CAMP
Price
$4.20Alerts
Change
-$0.13 (-3.00%)
Updated
Nov 11 closing price
Capitalization
254.78M
Intraday BUY SELL Signals
NERV
Price
$2.56Alerts
Change
+$0.07 (+2.81%)
Updated
Nov 11 closing price
Capitalization
115.55M
117 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CAMP vs NERV

CAMP vs NERV Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CAMP vs. NERV commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CAMP is a Hold and NERV is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CAMP with price predictions
Nov 11, 2026

CAMP's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for CAMP turned positive on October 27, 2026. Looking at past instances where CAMP's MACD turned positive, the stock continued to rise in 19 of 21 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on CAMP as a result. In 37 of 45 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

CAMP moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CAMP crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 8 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Following a +26.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAMP advanced for three days, in 73 of 86 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Bearish Trend Analysis

The 10-day RSI Indicator for CAMP moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 9 similar instances where the indicator moved out of overbought territory. In 9 of the 9 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 22 of 22 cases where CAMP's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

CAMP broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CAMP entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CAMP's P/B Ratio (-367.645) is very low in comparison to the industry average of (3.498). P/E Ratio (-1.758) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.095) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (45.249) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. CAMP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 75 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for NERV with price predictions
Nov 11, 2026

Momentum Indicator for NERV turns positive, indicating new upward trend

NERV saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 74 similar instances where the indicator turned positive. In 64 of the 74 cases, the stock moved higher in the following days. The odds of a move higher are at 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NERV's RSI Indicator exited the oversold zone, 22 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.

The Moving Average Convergence Divergence (MACD) for NERV just turned positive on October 28, 2026. Looking at past instances where NERV's MACD turned positive, the stock continued to rise in 31 of 39 cases over the following month. The odds of a continued upward trend are 79%.

Following a +14.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where NERV advanced for three days, in 192 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NERV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

NERV broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for NERV entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.542) is normal, around the industry mean (3.498). P/E Ratio (-0.067) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.160) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. NERV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NERV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
NERV: Fundamental Ratings
NERV
OUTLOOK RATING
1..100
35
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
84
P/E GROWTH RATING
1..100
11
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CAMPNERV
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
79%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
86%
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
80%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 17 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
86%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (CAMP: $4.20 vs. NERV: $2.56)
Brand notoriety: CAMP and NERV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CAMP: 36% vs. NERV: 52%
Market capitalization -- CAMP: $254.78M vs. NERV: $115.55M
CAMP [@Biotechnology] is valued at $254.78M. NERV’s [@Biotechnology] market capitalization is $115.55M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CAMP’s FA Score shows that 1 FA rating(s) are green while NERV’s FA Score has 1 green FA rating(s).

  • CAMP’s FA Score: 1 green, 4 red.
  • NERV’s FA Score: 1 green, 4 red.
According to our system of comparison, both CAMP and NERV are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CAMP’s TA Score shows that 5 TA indicator(s) are bullish while NERV’s TA Score has 4 bullish TA indicator(s).

  • CAMP’s TA Score: 5 bullish, 5 bearish.
  • NERV’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both CAMP and NERV are a good buy in the short-term.

Price Growth

CAMP (@Biotechnology) experienced а +12.30% price change this week, while NERV (@Biotechnology) price change was -0.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.

Reported Earning Dates

NERV is expected to report earnings on Mar 09, 2027.

Industries' Descriptions

@Biotechnology (-0.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

CAMP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CAMP has been loosely correlated with RLMD. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if CAMP jumps, then RLMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CAMP
1D Price
Change %
CAMP100%
-3.00%
RLMD - CAMP
34%
Loosely correlated
+3.75%
TARA - CAMP
34%
Loosely correlated
+7.82%
NERV - CAMP
32%
Poorly correlated
+2.81%
RCKT - CAMP
31%
Poorly correlated
+1.22%
RNAC - CAMP
29%
Poorly correlated
-0.15%
More

NERV and

Correlation & Price change

A.I.dvisor indicates that over the last year, NERV has been loosely correlated with ANRO. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if NERV jumps, then ANRO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NERV
1D Price
Change %
NERV100%
+2.81%
ANRO - NERV
50%
Loosely correlated
+8.88%
DMRA - NERV
45%
Loosely correlated
-3.73%
RLMD - NERV
40%
Loosely correlated
+3.75%
SION - NERV
40%
Loosely correlated
N/A
BNTC - NERV
37%
Loosely correlated
+2.05%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
GRNJ25.850.68
+2.70%
Fundstrat Granny Shots US Small & Mid Cap ETF
NITE37.030.45
+1.22%
The Nightview Fund ETF (NITE)
IHDG53.130.31
+0.59%
WisdomTree International Hedged Quality Dividend Growth Fund (IHDG)
FCXG14.48N/A
N/A
Leverage Shares 2x Long FCX Daily ETF (FCXG)
IONX14.02-0.78
-5.27%
Defiance Daily Target 2X Long IONQ ETF (IONX)